| abstract |
The present invention provides a dry powder inhaler comprising: a dry powder medicament comprising fluticasone propionate, salmeterol xinafoate, and a lactose carrier; wherein delivery of fluticasone propionate per actuation The dose is less than 100 micrograms; and wherein within 30 minutes after receiving the dose, the dose provides a baseline adjusted FEV1 of greater than 150 milliliters in the patientn. A method of treating a patient comprises: administering to a patient a dry powder medicament comprising fluticasone propionate, salmeterol xinafoate, and a lactose carrier; wherein delivery of fluticasone propionate per actuation The dose is less than 100 micrograms; and wherein within 30 minutes after receiving the dose, the dose provides a baseline adjusted FEV1 of greater than 150 milliliters in the patientn. |